ETP Ventures
VC Fund
ETP Ventures is a VC fund focused on Health Care and Biotechnology. ETP Ventures
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries ETP Ventures invests in
Stages ETP Ventures invests in
Countries ETP Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 4 (100%)
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Nutrition 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Angel 1 (25%)
Country
- China 2 (50%)
- Hong Kong 1 (25%)
- Switzerland 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dr. Liu Xiaoling
Senior Investment Manager
|
Senior Investment Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SEIMEI is a nutrition and anti-aging biotechnology brand. | $4M / Seed / Nov 18, 2022 | ||
| Deep Longevity is a biotechnology company transforming longevity R&D through AI-discovered biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types. | Series A / Jul 14, 2020 | ||
| Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies. | Angel / Sep 11, 2019 | ||
| Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland. | $20.1M / Series A / Dec 19, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ETP Ventures invest in?
ETP Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ETP Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ETP Ventures?
The team at ETP Ventures includes Dr. Liu Xiaoling (Senior Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
